Search

Your search keyword '"McNally, Orla"' showing total 341 results

Search Constraints

Start Over You searched for: Author "McNally, Orla" Remove constraint Author: "McNally, Orla"
341 results on '"McNally, Orla"'

Search Results

2. Targeting homologous recombination deficiency in uterine leiomyosarcoma

3. Interferon-ε is a tumour suppressor and restricts ovarian cancer

4. Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer

7. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer

8. Natural history of pelvic floor disorders before and after hysterectomy for gynaecological cancer.

9. Abstract B019: Assessing Circulating TumOur DNA as a prognostic biomarker in endometrial cancer (The CODEC Study)

10. Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial

11. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

12. Excisional treatment comparison for in situ endocervical adenocarcinoma (EXCISE): A phase 2 pilot randomized controlled trial to compare histopathological margin status, specimen size and fragmentation after loop electrosurgical excision procedure and cold knife cone biopsy

13. Contraceptive strategies for reducing the risk of reproductive cancers.

14. Low‐risk gestational trophoblastic neoplasia – 20 years experience of a state registry.

16. Therapeutic options for mucinous ovarian carcinoma

18. Analysis of Anxiety, Depression and Fear of Progression at 12 Months Post-Cytoreductive Surgery in the SOCQER-2 (Surgery in Ovarian Cancer—Quality of Life Evaluation Research) Prospective, International, Multicentre Study

19. Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer

21. PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors

23. ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer

27. EP362/#696 New patient-derived models and therapy screening in mucinous ovarian carcinoma

29. Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin

30. Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin

31. #824 The correlation between macroscopic surgical assessment, histological and molecular subtypes of high-grade serous cancer of the female genital tract, ovarian, tubal and peritoneal origin- the FOoTPrint study

36. Analysis of Anxiety, Depression and Fear of Progression at 12 Months Post-Cytoreductive Surgery in the SOCQER-2 (Surgery in Ovarian Cancer—Quality of Life Evaluation Research) Prospective, International, Multicentre Study.

37. Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care

38. Supplementary Tables from Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma

39. Table S4 from Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer

40. Supplementary Data from Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer

41. Data from LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin

42. Supplementary Figures 1-10 from LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin

43. Supplementary Methods from LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin

44. Supplementary Tables 1-6 from LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin

46. Shifting incidence and survival of epithelial ovarian cancer (1995-2014):A SurvMark-2 study

47. The molecular origin and taxonomy of mucinous ovarian carcinoma

48. The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.

50. Shifting incidence and survival of epithelial ovarian cancer (1995‐2014): A SurvMark‐2 study

Catalog

Books, media, physical & digital resources